Content |
Pharm Aid LLC was formed in May 2017 as a joint venture between Ishwan Pharmaceuticals and the Rostec State Corporation. In 2017, a technology transfer agreement was signed with the Serum Institute of India, Zydus Cadila and Mylan Laboratories. In June 2021, the company registered a vaccine in Russia for the prevention of rotavirus infection.
History
2021: Start of construction of the full cycle complex in the industrial park "Vorsino"
In early October 2021, Rostec and Rusnano agreed to launch the production of live and inactivated vaccines. Another partner in this project will be Ishwan Pharmaceutical.
Under the terms of the agreement, a unique production complex for the production of vaccines for the prevention of rotavirus infection and chickenpox, and in the future from other diseases, will be created in the Vorsino Kaluga industrial park.
The company will use the technological processes of the world's largest vaccine manufacturer, a company with full localization in Russia. It is assumed that by 2025 the production capacity of the new enterprise will reach 4 million doses of drugs per year, and 2026 - already more than 8 million.
The production will be organized on the basis of the pharmaceutical company Farm Aid, which is a joint venture of Rostec Group of Companies and Ishvan Pharmaceutical. The new enterprise will use the technological processes of one of the world's largest vaccine manufacturers - the Serum Institute of India - with full localization in Russia.
On October 4, 2021 pharmaceutical , Farm Aid confirmed that it was starting to create its own full-cycle biopharmaceutical production complex based on a partially built facility located in Vorsino Industrial Park (). Kaluga region
The land plot with the objects of unfinished construction was acquired from NovaMedica (part of the Rusnano group), the documents on the transfer of property rights were signed on September 21, 2021 in Moscow in the presence of shareholders and management of both companies.
The biopharmaceutical complex with an area of more than 20 thousand square meters. meters is planned to be launched at the end of 2024.
 | We intend to create a full-cycle production complex designed using high-speed technologies for the production of "living" and inactivated vaccines, as well as monoclonal antibodies. Our strategy provides for the phased localization of production from secondary packaging, bottling and to the development of antigens. At the initial stage, the plant's production capacity will be more than 4 million doses of vaccines per year, said Azamat Metov, general director of Farm Aid. - For a long time we looked for a place to localize production in Russia and considered various options. Opportunities from the deal with NovaMedika in combination with the infrastructure of the Vorsino industrial park will allow us to start production as soon as possible. |  |
Farm Aid has entered into a technology licensing agreement with Indian vaccine manufacturer Serum Institute of India Pvt. Ltd., as well as with the Indian pharmaceutical company Zydus Cadila. The Serum Institute team will accompany the process of creating the Farm Aid production complex.
| | In the Russian pharmaceutical market, we are represented by partners - Farm Aid, together with which we plan to transfer technologies for the full production cycle of a number of vaccines, "said the Director of the Serum Institute of India in Russia. - It is worth noting that Russia is for us a strategic direction of business development, and we are glad to start implementing the plan conceived together with Farm Aid. | |
| | The Russian pharmaceutical market has always been a priority for us, the creation of our own production infrastructure opens up great prospects for us. Introducing innovations by localizing and transferring technologies from the world's largest manufacturers, as well as looking to the future on mRNA technology, will allow us to take one of the highest positions in the market in a short time - said Director of the company Ishwan Sanjiv Nanda. | |
| | The resumption of the construction of a complex for the production of biological drugs in Vorsino confirms the suitability of the strategic vector for localizing production in the Russian Federation of the entire spectrum of technologies and products most sensitive to the national health system, which, of course, include vaccines against socially significant, including childhood diseases, commented on the acquisition of the site. Managing Director for Investment Activities of Rusnano LLC Olga Shpichko. | |
In 2024, it is planned to launch the production of a vaccine for the prevention of rotavirus infection at the site in the Kaluga region, the registration certificate for which was received by Farm Aid at the end of June 2021.
Senior Managing Director of Rusnano Management Company Ivan Ozhgikhin noted that the implementation of this project will contribute to the import substitution of vaccines. The capacity of the new biopharmaceutical production will close the national calendar of preventive vaccinations with fully domestic vaccines. Such a task is set in the message of Russian President Vladimir Putin. In addition, the project involves the creation of a center of scientific competencies for conducting research, development and bringing its own products and technologies to the market in the future, which is fully consistent with the goals and objectives formulated in the strategy of the Rusnano group as a development institute, he added.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |